Fractyl's Revita has its trial win and a funding gap

The technology

Revita is a one-time endoscopic ablation procedure that Fractyl is developing to help people keep weight off after they stop GLP-1 drugs. It has FDA Breakthrough Device Designation for post-GLP-1 weight maintenance.

The registrational evidence is now in hand for the first of two co-primary endpoints. In the 308-patient REMAIN-1 registrational cohort, people who lost at least 15% of body weight on tirzepatide and then stopped regained 5.1% of body weight after Revita against 8.2% after sham at six months (p=0.0023). That is about 80% of the lost weight kept, against 67%. There were no device- or procedure-related serious adverse events. A post hoc look found less regain with longer ablations.

The effect is real but modest: 3.1 points of body weight at six months. The randomized midpoint cohort showed a wider gap at one year, 7.8% against 13.0%, in 45 patients.

The odds

Revita is a device going through FDA's De Novo pathway, so the drug base rates in the BIO, Informa and QLS 2011 to 2020 study do not map neatly. For reference, drugs in phase 3 reached approval 52.4% of the time, and 90.6% of filed drugs were approved.

Two facts help Revita. One co-primary endpoint is met with a clear p-value. The second, more than 50% of patients keeping at least 5% weight loss at 12 months, is a performance goal set by FDA, and the midpoint cohort reached 73%. The open regulatory question is safety review: FDA said final pathway decisions depend on the complete safety dataset.

The money

Fractyl reported $63.2 million in cash at March 31, 2026, with a first-quarter operating loss of $20.8 million. On October 22 it cut about 45% of staff, dropped internal development of its Rejuva gene therapy and guided that cash would last into the second quarter of 2027. Quarterly operating burn is expected to fall to about $8 million by the end of that quarter.

The timeline does not line up with the cash. Potential FDA authorization is expected in late 2027 and a U.S. launch in early 2028. Fractyl hired a market access head, Mike Zumdahl, in June, and a Category III CPT code for the procedure starts on January 1, 2027.

The risks

Funding comes first. The company will likely need new capital or a partner to cover the months between its runway and a launch.

The 12-month endpoint is the second risk. A miss on the 50% performance goal would undercut the filing, though the midpoint data make that less likely.

The third is commercial. Patients and payers will have to decide whether avoiding about three points of regain is worth an endoscopic procedure. Fractyl presented its market case at a commercial strategy day on September 1, citing about 30 million U.S. adults on GLP-1 therapy.

Our read

Revita did what it needed to in the registrational trial, with a statistically clear result and a clean safety record so far. The size of the benefit is the soft spot, and the market's reaction to the readout suggests investors had hoped for more.

Fractyl is now a one-product company with a filing planned for late 2026 and cash into mid-2027. The 12-month data in the first quarter of 2027 are the next hard test, and the terms of the financing that follows will shape what Revita is worth to current holders.